Phase 2 study of imexon, a prooxidant molecule, in relapsed and refractory B-cell non-Hodgkin lymphoma
Paul M. Barr(University of Rochester Medical Center), Margaret M. Briehl(University of Arizona), Denise J. Roe(University of Arizona), Haiyan Cui(Tongji University), Jonathan W. Friedberg(University of Rochester), Jamie Littleton(University of Rochester), Derick R. Peterson(University of Rochester), Carla Casulo(University of Rochester Medical Center), Daniel O. Persky(Universidad San Carlos), Andrea Baran(Hospital of the University of Pennsylvania), Megan M. Herr(Roswell Park Comprehensive Cancer Center), Mark W. Schwartz(Environmental Protection Agency), Thomas P. Miller(Queen Elizabeth University Hospital), Robert T. Dorr(SWOG Cancer Research Network), Richard I. Fisher(University of Rochester), Terry H. Landowski(University of Arizona), Steven H. Bernstein(University of Rochester), Soham D. Puvvada(University of Arizona), Catherine Spier(University of Utah), Lisa M. Rimsza(Banner - University Medical Center Tucson)
Cited by 37
Related Papers
Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma
|New England Journal of Medicine|2017|6k
The Use of Molecular Profiling to Predict Survival after Chemotherapy for Diffuse Large-B-Cell Lymphoma
|New England Journal of Medicine|2002|3.9k
Genetics and Pathogenesis of Diffuse Large B-Cell Lymphoma
|New England Journal of Medicine|2018|2.3k
Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia
|New England Journal of Medicine|2015|1.9k
Stromal Gene Signatures in Large-B-Cell Lymphomas
|New England Journal of Medicine|2008|1.8k